Statistical evaluation of surrogate endpoints with examples from cancer clinical trials-Reference-Cited by-同舟云学术

Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

Published:2015-02-12 Issue:1 Volume:58 Page:104-132
ISSN:0323-3847
Container-title:Biometrical Journal
language:en
Short-container-title:Biom. J.

Author:

Buyse Marc¹²,Molenberghs Geert²³,Paoletti Xavier⁴,Oba Koji⁵,Alonso Ariel³,Van der Elst Wim²,Burzykowski Tomasz²⁶

Affiliation:

1. International Drug Development Institute (IDDI); 185 Alewife Brook Parkway, Suite 410 Cambridge MA 02138 USA

2. Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat); Hasselt University; Martelarenlaan 42 3500 Hasselt Belgium

3. Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat); KU Leuven-University of Leuven; Kapucijnenvoer 35 3000 Leuven Belgium

4. Department of Biostatistics; INSERM U900, Institut Curie; 26 Rue d'Ulm 75005 Paris France

5. Department of Biostatistics; School of Public Health, Graduate School of Medicine, and Interfaculty Initiative in Information Studies, University of Tokyo; 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan

6. International Drug Development Institute (IDDI); avenue provinciale 30 1340 Louvain-la-Neuve Belgium

Publisher

Wiley

Subject

Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability

Reference87 articles.

1. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements;Alonso;Biometrical Journal,2003

2. Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints;Alonso;Biometrics,2004

3. A unifying approach for surrogate marker validation based on Prentice's criteria;Alonso;Statistics in Medicine,2005

4. Surrogate marker evaluation from an information theoretic perspective;Alonso;Biometrics,2007

5. Alonso , A. Van der Elst , W. Molenberghs , G. Buyse , M. Burzykowski , T. 2014 On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints. Biometrics

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishing and Using Threshold of Surrogate Endpoint in Relation to Clinical Endpoint;Statistics in Biopharmaceutical Research;2024-08-28

2. Statistical approaches for component-wise censored composite endpoints;Clinical Trials;2024-08-08

3. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration;BMJ;2024-07-09

4. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration;BMJ;2024-07-09

5. Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint;Pharmaceutical Statistics;2024-07-02